OmicScouts GmbH

Key figures / Profile

• As leading chemical proteomics company, we integrate excellent research expertise and innovative technologies for drug and biomarker discovery
• We provide proteome-wide assays to identify drug targets, pharmacodynamic and target engagement markers, and for the analysis of molecular mechanisms of action and resistance formation
• TUM spin-off founded 2014 by leading proteomics researchers with a track record in delivering significant collaborations with top pharmaceutical and biotechnology companies

We offer

• End-to-end solutions for your project needs based on a comprehensive portfolio of proteomic technologies

• ProteomeScout™ - comprehensive and quantitative protein expression profiling for unbiased, proteome-wide target and biomarker discovery
• SignallingScout™ - comprehensive profiling of dynamic phosphorylation events in up to 100s of samples
• BiomarkerScout™ - accurate, sensitive and multiplexed quantification of up to hundred selected proteins across hundreds of samples
• Proteome dynamics profiling - determination of protein turnover in living cells, e.g. after drug treatment or stimulation
• TargetScout™ - identification of specific cellular targets of small molecules under physiological conditions with native, endogenously expressed proteins
• KinomeScout™ - selectivity and affinity profiling of protein kinase inhibitors to direct the design of potent and selective small molecule drug candidates